awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q36498695-54507815-BF0C-4988-A6FE-1915BA534434
Q36498695-54507815-BF0C-4988-A6FE-1915BA534434
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36498695-54507815-BF0C-4988-A6FE-1915BA534434
Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes.
P2860
Q36498695-54507815-BF0C-4988-A6FE-1915BA534434
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36498695-54507815-BF0C-4988-A6FE-1915BA534434
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
95b0fe82907eb6d30d9b2b5e6a1eef88e2ca040e
P2860
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes